The role of cytokines in pharmacological modulation of hepatic ischemia/reperfusion injury

Current Pharmaceutical Design

Volumn 12, Issue 23, 2006, Pages 2867-2873

  Husted, Thomas L ^a   Lentsch, Alex B ^a  

^a Department of Surgery   (United States)

Author keywords

Adhesion molecules; Chemokines; Cytokines; Inflammation; Ischemia reperfusion; Neutrophils; NF B

Indexed keywords

ALPHA CHEMOKINE; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STAT4 PROTEIN; STAT6 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

CELL DAMAGE; HUMAN; HYPOVOLEMIC SHOCK; INFLAMMATION; LEUKOCYTE; LIVER; LIVER ISCHEMIA; LIVER PARENCHYMA; LIVER RESECTION; LIVER TRANSPLANTATION; MEDIATOR; MODULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW;

ANIMALS; CYTOKINES; HUMANS; LIVER; LIVER DISEASES; REPERFUSION INJURY;

EID: 33746868270     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777947597     Document Type: Review

References (88)

1. Jaeschke H, Farhood A, Smith CW. Neutrophils contribute to iechemia/ reperfusion injury in rat liver in vivo. FASEB J 1900; 4: 3355-9.
2. Jeaschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia/reperfusion injury in rat liver. Am J Physiol 1991; 260(3 Pt 1): G355-62.
3. Jaeschke H, Smith CW. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997; 61(6): 647-53.
4. Vollmar B, Richter S, Menger MD. Leukocyte stasis in hepatic sinusoids. Am J Physiol 1996; 270(5 Pt 1): G798-803.
5. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170(3): 827-45.
6. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260(5107): 547-9.
7. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177(4): 1199-204.
8. Trinchieri G. Interleukmin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev 2003; 3: 133-146.
9. Myers KJ, Eppihimer MJ, Hall L, Wolitzky B. Interleukin-12-induced adhesion molecule expression in murine liver. Am J Pathol 1998; 152(2): 457-68.
10. Lentsch AB, Yoshidome H, Kato A, Warner RL, Chaedle WG, Ward PA, et al. Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 1999; 30(6): 1448-1453.
11. Kato A, Graul-Layman A, Edwards MJ, Lentsch AB. Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4. Transplantation 2002; 73(7): 1142-1145.
12. Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, Lassman CR, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology 2003; 37(2): 296-303.
13. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 1998; 9(3): 315-23.
14. Ethuin F, Delarche C, Benslama S, Gougerot-Pocidalo MA, Jacob L, Chollet-Martin S. Interleukin-12 increases interleukin 8 production and release by human polymorphonuclear neutrophils. J Leukoc Biol 2001; 70(3): 439-46.
15. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 1990; 10: 1498-1506.
16. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993; 13: 6231-40.
17. Stein B, Baldwin ASJ. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol 1993; 13: 7191-8.
18. Ohtsuka T, Kubota A, Hirano T, Watanabe K, Yoshida H, Tsurufuji M, et al. Glucocorticoid-mediated gene suppression of rat cytokine-induced neutrophil chemoattractant CINC/gro, a member of the interleukin-8 family, through impairment of NF-kappa B activation. J Biol Chem 1996; 271: 1651-9.
19. Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 1993; 150: 4996-5012.
20. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
21. Pahl HL. Activators and target genes of Re1/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-66.
22. Ghosh S, May MJ, Kopp EB. NF-kappa B and Re1 proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
23. Perkins ND, Schmid RM, Duckett CS, Leung K, Rice NR, Nabel G. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA 1992; 89: 1529-33.
24. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548-54.
25. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
26. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-6.
27. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
28. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162: 196-203.
29. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85: 1936-43.
30. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/ reperfusion injury and associated lung injury. Am J Pathol 1993; 143: 453-63.
31. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998; 10: 182-91.
32. Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein. J Clin Invest 1995; 95(1): 134-41.
33. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 1998; 27(4): 1172-7.
34. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54(2): 227-9.
35. Richardson RM, Pridgen BC, Haribabu B, Ali H, Snyderman R. Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation. J Biol Chem 1998; 273(37): 23830-6
36. Hall DA, Beresford IJ, Browning C, Giles H. Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol 1999; 126(3): 810-8.
37. Bender JG, McPhail LC, Van Epps DE. Exposure of human neutrophils to chemotactic factors potentiates activation of the respiratory burst enzyme. J Immunol 1983; 130(5): 2316-23.
38. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171(5): 1797-802.
39. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selectins and integrins. Crit Rev Immunol 1999; 19: 389-429
40. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003; 9: 263-8.
41. Kishimoto TK, Larson RS, Corbi AL, Dustin ML, Staunton DE, Springer TA. The leukocyte integrins. Adv Immunol 1989; 46: 149-82.
42. Radi ZA, Kehrli ME Jr, Ackermann MR. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med 2001; 15: 516-29.
43. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, et al. P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/ reperfusion injury. Am J Transplant 2002; 2: 600-8.
44. Misawa K, Toledo-Pereyra LH, Phillips ML, Garcia-Cirado FJ, Lopez-Neblina F, Paez-Rollys A. Role of sialyl Lewis(x) in total hepatic ischemia and reperfusion. J Am Coll Surg 1996; 182(3): 251-6.
45. Palma-Vargas JM, Toledo-Pereyra L, Dean RE, Harkema JM, Dixon RA, Kogan TP. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg 1997; 185(4): 365-72.
46. Kishimoto TK, Larson RS, Corbi AL, Dustin ML, Staunton DE, Springer TA. The leukocyte integrins. Adv Immunol 1989; 46: 149-82.
47. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284(1): G15-26.
48. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, Smith CW. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 1993; 17: 915-23.
49. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78.
50. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333-8.
51. Biffl W, Moore E, Moore F, Peterson V. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996; 224: 647-64.
52. Kita Y, Iwaki Y, Demetris A, Starzl T. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994; 57: 1037-41.
53. McCurry KR, Campbell DA Jr, Scales WE, Warren JS, Remick DG. Tumor necrosis factor, interleukin 6, and the acute phase response following hepatic ischemia/reperfusion. J Surg Res 1993; 55(1): 49-54.
54. Clavien PA, Camargo CA Jr, Gorczynski R, Washington MK, Levy GA, Langer B, et al. Acute reactant cytokines and neutrophil adhesion after warm ischemia in cirrhotic and noncirrhotic human livers. Hepatology 1996; 23(6): 1456-63.
55. Carmargo CA, Madden JF, Gao W, Selvin RS, Clavien PA. Interleukin-6 protects liver against warm ischemia-reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26(6): 1513-20.
56. Ulich T, Yin S, Guo K, Yi E, Remick D, Castillo J. Intratracheal injection of endotoxin and cytokines. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 1991; 138: 1097-1101.
57. Selzner M, Carmargo CA, Clavien PA. Ischemia impairs liver regeneration after major tissue loss in rodents: protective effects of interleukin-6. Hepatology 1999; 30: 469-75.
58. Taub R, Greenbaum LE, Peng Y. Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin Liver Dis 1999; 19(2): 117-27.
59. Cressman D, Greenbaum L, DeAngelis R, Ciliberto G, Furth E, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-83.
60. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990; 145(12): 4167-73.
61. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174(6): 1549-55.
62. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147(11): 3815-22.
63. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998; 28(6): 1597-606.
64. Conti F, Boulland ML, Leroy-Viard K, Chereau C, Dousset B, Soubrane O, et al. Low level of interleukin 10 synthesis during liver allograft rejection. Lab Invest 1998; 78(10): 1281-9.
65. Oreopoulos GD, Wu Heshui, Szaszi K, Fan J, Marshall JC, Khadaroo RG, et al. Hypertonic preconditioning prevents hepatocellular injury following ischemia/reperfusion in mice: a role for interleukin-10. Hepatology 2004; 40: 211-20.
66. Kato A, Okaya T, Lentsch AB. Endogenous IL-13 protects hepatocytes and vascular endothelial cells during ischemia/reperfusion injury. Hepatology 2003; 37: 304-12.
67. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor κB. Hepatology 1999; 30: 203-8.
68. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274(45): 31868-74.
69. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100(l0): 2443-8.
70. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 inhibits pulmonary NF-κB activation and lung injury induced by hepatic ischemia/ reperfusion. Am J Physiol (Lung Cell Mol Physiol) 1999; 277: L919-L923.
71. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-38.
72. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-56.
73. Kato A, Yoshidome H, Edwards MJ, Lentscb AB. Reduced hepatic ischemia/ reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflamm Res 2000; 49: 275-9.
74. Yoshidome H, Kato A, Miyazaki M, Edwards MJ, Lentsch AB. IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am J Physiol 1999; 155(4): 1059-64.
75. Ke B, Shen XD, Lassman CR, Gao F, Busuttil RW, Kupiec-Weglinski JW. Cytoprotective and anti-apoptotic effects of IL-13 in hepatic cold ischemia/reperfusion injury are heme oxygenase-1 dependent. Am J Transplant 2003; 3: 1076-1108.
76. Ke B, Shen XD, Lassman CR, Gao F, Katori M, Busuttil RW, et al. IL-13 gene transfer protects rat livers from antigen-independent injury induced by ischemia and reperfusion. Transplantation 2003; 75: 1118-23.
77. Izuhara K, Heike T, Otsuka T, Yamaoka K, Mayumi M, Imamura T, et al. Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X-linked severe combined immunodeficiency patients. J Biol Chem 1996; 271: 619-22.
78. Kato A, Yoshidome H, Edwards MJ, Lentsch AB. Regulation of liver inflammatory injury by signal transducer and activator of transcription. Am J Pathol 2000; 157: 297-302.
79. Ke B, Shen XD, Gao F, Busuttil RW, Kupiec-Weglinski JW. Interleukin-13 gene transfer in liver ischemia and reperfusion injury: role of STAT6 and TLR4 pathways in cytoprotection. Hum Gene Ther 2004; 15: 691-98.
80. Woods JM, Amin A, Katschke KJ, Volin MV, Ruth JH, Connors MA, et al. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 2002; 13: 381-93.
81. Tomee JF, Koeter GH, Hiemstra PS, Kauffman HF. Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax 1998; 53(2): 114-6.
82. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, et al. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 1997; 3(Suppl 1): S64-9.
83. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ. Secretory leukovyte inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 1999; 117: 953-61.
84. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, et al. Inhibition of NF-κB activation and augmentation of IκBα by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154: 239-47.
85. Mulligan MS, Lentsch AB, Huber-Lang M, Goo RF, Sarma V, Wright CD, et al. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 2000; 156(3): 1033-9.
86. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 2005; 11(28): 3697-710.
87. Jin H, Wyss JM, Yang R, Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004; 10(20): 2525-33.
88. Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 2004; 10(11): 1245-59.